Infection and Drug Resistance,
Journal Year:
2020,
Volume and Issue:
Volume 13, P. 3409 - 3422
Published: Oct. 1, 2020
Background:
The
emerging
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
resulted
in
a
worldwide
devastating
effect
with
diagnostic
challenge.
Identifying
risk
factors
of
severity
aids
assessment
for
the
need
early
hospitalization.
We
aimed
to
demonstrate,
first
time,
clinical,
laboratory
and
radiological
characteristics
disease
2019
(COVID-19)
patients,
identify
predictors
describe
antimicrobial
resistance
profile
patients
from
Upper
Egypt.
Materials
Methods:
Demographic
characters,
clinical
presentations,
laboratory,
data
were
recorded
analyzed.
Presence
other
microorganisms
their
sensitivity
patterns
identified
using
VITEK2
system.
Resistance-associated
genes
tested
by
PCR.
Results:
study
included
260
COVID-19
patients.
majority
males
(55.4%)
aged
between
51
70
years.
Hypertension,
diabetes,
ischemic
heart
common
comorbidities.
Main
manifestations
fever
(63.8%),
cough
(57.7%),
dyspnea
(40%)
fatigue
(30%).
According
severity,
51.5%
moderate,
25.4%
mild
23%
severe/critical.
Lymphopenia,
elevated
CRP,
ferritin,
D-dimer
occurred
all
significantly
higher
value
group.
Age
>
53
years
ferritin
≥
484
ng/mL
significant
severity.
About
10.7%
showed
bacterial
and/or
fungal
infections.
Klebsiella
pneumoniae,
Acinetobacter
baumannii
,
Staphylococcus
aureus
predominant
isolated
bacteria
while
Candida
albicans
glabrata
fungi.
All
Staphylococci
methicillin-resistant
carried
mecA
gene.
Gram-negative
isolates
multidrug-resistant
different
resistance-associated
genes,
including
NDM-1,
KPC,
TEM,
CTX-M
SHV.
Conclusion:
Older
age
serum
COVID-19.
Bacterial
co-infection
multidrug
among
Egypt
is
common.
Testing
presence
co-infecting
agents
should
be
considered,
prompt
treatment
out
according
reports.
Keywords:
COVID-19,
characteristics,
ESBL,
factors,
Nature Reviews Chemistry,
Journal Year:
2021,
Volume and Issue:
5(10), P. 726 - 749
Published: Aug. 19, 2021
An
ever-increasing
demand
for
novel
antimicrobials
to
treat
life-threatening
infections
caused
by
the
global
spread
of
multidrug-resistant
bacterial
pathogens
stands
in
stark
contrast
current
level
investment
their
development,
particularly
fields
natural-product-derived
and
synthetic
small
molecules.
New
agents
displaying
innovative
chemistry
modes
action
are
desperately
needed
worldwide
tackle
public
health
menace
posed
antimicrobial
resistance.
Here,
our
consortium
presents
a
strategic
blueprint
substantially
improve
ability
discover
develop
new
antibiotics.
We
propose
both
short-term
long-term
solutions
overcome
most
urgent
limitations
various
sectors
research
funding,
aiming
bridge
gap
between
academic,
industrial
political
stakeholders,
unite
interdisciplinary
expertise
order
efficiently
fuel
translational
pipeline
benefit
future
generations.
Applied Microbiology and Biotechnology,
Journal Year:
2020,
Volume and Issue:
104(18), P. 7777 - 7785
Published: Aug. 11, 2020
The
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2),
a
novel
β-coronavirus,
is
the
main
pathogenic
agent
of
rapidly
spreading
pneumonia
called
disease
2019
(COVID-19).
SARS-CoV-2
infects
much
more
people,
especially
elder
population,
around
world
than
other
coronavirus,
such
as
SARS-CoV
and
MERS-CoV,
which
challenging
current
global
public
health
system.
Beyond
pathogenesis
SARS-CoV-2,
microbial
coinfection
plays
an
important
role
in
occurrence
development
infection
by
raising
difficulties
diagnosis,
treatment,
prognosis
COVID-19,
even
increasing
symptom
mortality.
We
summarize
virus,
bacteria
fungi
with
their
effects
on
reasons
coinfection,
diagnosis
to
emphasize
importance
COVID-19.
KEY
POINTS:
•
Microbial
nonnegligible
factor
exacerbates
processes
occurrence,
clinical
treatment.
Different
bacteria,
contributed
SARS-CoV-2.
Antibiotics,
Journal Year:
2022,
Volume and Issue:
11(4), P. 427 - 427
Published: March 23, 2022
Antimicrobial
resistance
(AMR)
has
emerged
as
a
major
threat
to
public
health
globally.
Accurate
and
rapid
detection
of
antimicrobial
drugs,
subsequent
appropriate
treatment,
combined
with
stewardship,
are
essential
for
controlling
the
emergence
spread
AMR.
This
article
reviews
common
susceptibility
testing
(AST)
methods
relevant
issues
concerning
advantages
disadvantages
each
method.
Although
accurate,
classic
technologies
used
in
clinical
microbiology
profile
time-consuming
relatively
expensive.
As
result,
physicians
often
prescribe
empirical
therapies
broad-spectrum
antibiotics.
recently
developed
AST
systems
have
shown
over
traditional
terms
speed
potential
providing
deeper
insight
into
mechanisms,
extensive
validation
is
required
translate
these
methodologies
practice.
With
continuous
increase
resistance,
additional
efforts
needed
develop
innovative,
rapid,
portable
diagnostic
tools
AST.
The
wide
implementation
novel
devices
would
enable
identification
optimal
treatment
approaches
surveillance
antibiotic
health,
agriculture,
environment,
allowing
monitoring
better
tackling
Pneumonia,
Journal Year:
2021,
Volume and Issue:
13(1)
Published: April 24, 2021
Abstract
Background
It
has
been
recognised
for
a
considerable
time-period,
that
viral
respiratory
infections
predispose
patients
to
bacterial
infections,
and
these
co-infections
have
worse
outcome
than
either
infection
on
its
own.
However,
it
is
still
unclear
what
exact
roles
and/or
superinfections
play
in
with
COVID-19
infection.
Main
body
This
was
an
extensive
review
of
the
current
literature
regarding
SARS-CoV-2
The
definitions
used
were
those
Centers
Disease
Control
Prevention
(US),
which
defines
coinfection
as
one
occurring
concurrently
initial
infection,
while
are
follow
previous
especially
when
caused
by
microorganisms
resistant,
or
become
antibiotics
earlier.
Some
researchers
envisioned
three
potential
scenarios
bacterial/SARS-CoV-2
co-infection;
namely,
secondary
following
colonisation,
combined
viral/bacterial
pneumonia,
superinfection
SARS-CoV-2.
There
myriad
published
articles
ranging
from
letters
editor
systematic
reviews
meta-analyses
describing
varying
ranges
co-infection
COVID-19.
concomitant
described
included
other
viruses,
bacteria,
including
mycobacteria,
fungi,
well
other,
more
unusual,
pathogens.
will
be
seen
this
review,
there
often
not
clear
distinction
made
authors
referring
to,
whether
true
concomitant/co-infections
superinfections.
In
addition,
possible
mechanisms
interactions
between
SARS-CoV-2,
particularly
discussed
further.
Lastly,
impact
severity
their
also
described.
Conclusion
describes
rates
although
two
literature.
When
they
occur,
appear
associated
both
poorer
outcomes.
IUBMB Life,
Journal Year:
2020,
Volume and Issue:
72(10), P. 2097 - 2111
Published: Aug. 8, 2020
Abstract
The
pandemic
coronavirus
disease
2019
(COVID‐19),
caused
by
Severe
Acute
Respiratory
Syndrome
Coronavirus
2
(SARS‐CoV‐2),
has
affected
millions
of
people
worldwide.
To
date,
there
are
no
proven
effective
therapies
for
this
virus.
Efforts
made
to
develop
antiviral
strategies
the
treatment
COVID‐19
underway.
viral
infections,
such
as
influenza,
predispose
patients
co‐infections
and
these
lead
increased
severity
mortality.
Numerous
types
antibiotics
azithromycin
have
been
employed
prevention
bacterial
co‐infection
secondary
infections
in
with
a
respiratory
infection
(e.g.,
SARS‐CoV‐2).
Although
do
not
directly
affect
SARS‐CoV‐2,
often
result
pneumonia.
It
is
possible
that
some
die
from
rather
than
virus
itself.
considerable
number
strains
resistant
various
azithromycin,
overuse
could
render
those
or
other
even
less
effective.
Therefore,
considered
critical
risk
factors
mortality
rates
COVID‐19.
Also,
antibiotic‐resistant
overusing
must
be
considered.
In
review,
we
will
summarize
featured
especially
EMBO Molecular Medicine,
Journal Year:
2020,
Volume and Issue:
12(7)
Published: May 26, 2020
Respiratory
viral
infections
are
well
known
to
predispose
patients
bacterial
co-infections
and
superinfections.
Still,
there
is
limited
reference
these
in
COVID-19.
Do
play
a
significant
role
during
COVID-19?
What
the
impact
of
antimicrobial
resistance?
Eurosurveillance,
Journal Year:
2020,
Volume and Issue:
25(45)
Published: Nov. 12, 2020
Preview
this
article:
Will
coronavirus
disease
(COVID-19)
have
an
impact
on
antimicrobial
resistance?,
Page
1
of
<
Previous
page
|
Next
>
/docserver/preview/fulltext/eurosurveillance/25/45/eurosurv-25-45-1-1.gif
Scientific Reports,
Journal Year:
2021,
Volume and Issue:
11(1)
Published: May 24, 2021
Physicians
taking
care
of
patients
with
coronavirus
disease
(COVID-19)
have
described
different
changes
in
routine
blood
parameters.
However,
these
changes,
hinder
them
from
performing
COVID-19
diagnosis.
We
constructed
a
machine
learning
predictive
model
for
The
was
based
and
cross-validated
on
the
tests
5,333
various
bacterial
viral
infections,
160
COVID-19-positive
patients.
selected
operational
ROC
point
at
sensitivity
81.9%
specificity
97.9%.
area
under
curve
(AUC)
0.97.
five
most
useful
parameters
COVID19
diagnosis
according
to
feature
importance
scoring
XGBoost
algorithm
were
MCHC,
eosinophil
count,
albumin,
INR,
prothrombin
activity
percentage.
tSNE
visualization
showed
that
severe
course
are
more
like
than
infection.
reported
diagnostic
accuracy
is
least
comparable
probably
complementary
RT-PCR
chest
CT
studies.
Patients
fever,
cough,
myalgia,
other
symptoms
can
now
initial
assessed
by
our
tool.
All
positive
prediction
would
then
undergo
standard
studies
confirm
believe
results
present
significant
contribution
improvements